S786
Clinical - Lung
ESTRO 2026
Eligibility required a tumor diameter ≤ 5 cm. Patients received SBRT delivered in eight fractions. Treatment planning followed pre-trial quality assurance procedures outlined in the study protocol (Clinicaltrials.gov ID NCT05354596)2. Primary dose planning priority was organ-at-risk (OAR) constraints, second priority target coverage, aiming for 95% of the PTV to receive 95% of the prescribed 56 Gy dose, allowing dose escalation within the gross tumor volume (GTV) to mean doses up to 85 Gy2. Toxicities were prospectively recorded and graded using CTCAE version 5.0. The primary endpoint was the incidence of Grade 4–5 toxicity, while secondary endpoints included overall survival (OS) and overall toxicity. Results:
precision on the estimated risks of RT. Keywords: nsclc, ild, radiotherapy
Proffered Paper 2294 Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) for Centrally Located Lung Tumors: Interim Results from the Multicenter STRICT Lung Trial Mette Pøhl 1 , Gitte Fredberg Persson 2 , Marianne Marquard Knap 3 , Cécile Peucelle 1 , Ivan Richter Vogelius 1 , Lotte Nygård 1 , Simon Nyberg Thomsen 3,4 , Laura Ann Rechner 2 , Azza Ahmed Khalil 5 , Charlotte Kristiansen 6 , Lotte Holm Land 7 , Morten Nielsen 8 , Tine Bjørn Nielsen 8 , Hella Brøgger Sand 9,10 , Wiviann Ottosson 2 , Filippa Sundbye 2 , Weronika Maria Szejniuk 9,10 , Ditte Sloth Møller 5,11 , Tine Schytte 7,12 , Ane Appelt 1,13 , Lone Hoffmann 5,4 1 Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. 2 Department of Oncology, Copenhagen University Hospital - Herlev and Gentofteopenhagen University Hospital - Rigshospitalet, Herlev, Denmark. 3 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 4 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 5 Department of Oncology, Aarhus University HospitalCopenhagen University Hospital - Rigshospitalet, Aarhus, Denmark. 6 Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark. 7 Department of Oncology, Odense University Hospital, Odense, Denmark. 8 Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark. 9 Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 10 Deptment of Clinical Medicine, Aalborg University, Aalborg, Denmark. 11 Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. 12 Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 13 Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom Purpose/Objective: The STRICT Lung trial is a prospective, multicenter, phase II study evaluating the safety and efficacy of stereotactic body radiotherapy (SBRT) for centrally located lung tumors including primary, oligo- metastatic, or oligo-progressive disease. Previous studies have reported high rates of severe and even fatal toxicity involving central and perihilar structures1. We report feasibility and safety outcomes after SBRT in 98 patients with centrally located tumors. Material/Methods: Centrally located solid tumors were defined as within 0.5-2.5 cm of the proximal bronchial tree (PBT) or esophagus, or within 0.5 cm of the heart or aorta.
Between February 2022 and October 2025, 100 patients were enrolled across five Danish centres. Two withdrew consent, leaving 98 treated: 73 with primary lung cancer and 25 with pulmonary metastases (Table 1). The median follow-up time was 9.6 months (IQR 3.6-20.9 months) from treatment initiation. Ten patients had > 1 target lesion. Two grade 5 (2%)
Made with FlippingBook - Share PDF online